Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Case report

A word of caution: do not wake sleeping dogs; micrometastases of melanoma suddenly grew after progesterone treatment

Jose Mordoh12, Ivana Jaqueline Tapia2 and Maria Marcela Barrio2*

Author Affiliations

1 Instituto Alexander Fleming, Cramer 1180, Buenos Aires, Argentina

2 Centro de Investigaciones Oncológicas-Fundación Cáncer, Cramer 1180, Buenos Aires, Argentina

For all author emails, please log on.

BMC Cancer 2013, 13:132  doi:10.1186/1471-2407-13-132

Published: 20 March 2013

Abstract

Background

Hormonal treatment might affect the immune response to tumor antigens induced in cancer patients who are being vaccinated.

Case presentation

A 33 years-old woman was diagnosed with cutaneous melanoma in May 2009. Her melanoma was located in the intermammary sulcus, had a Breslow thickness of 4 mm, a Clark’s level IV, it was ulcerated and highly melanotic. The bilateral sentinel node biopsy was negative. She entered into a randomized Phase II/III clinical study comparing a vaccine composed of irradiated melanoma cells plus BCG plus GM-CSF versus IFN-alpha 2b and she was assigned to the vaccine arm. During the two years treatment she remained disease-free; the final CAT scan being performed in August 2011. Between November and December 2011, her gynecologist treated her with three cycles of 200 mg progesterone/day for ten days, every two weeks, for ovary dysfunction. In November 2011 the patient returned to the Hospital for clinical and imaging evaluation and no evidence of disease was found. At the next visit in March 2012 an ultrasound revealed multiple, large metastases in the liver. A CAT scan confirmed the presence of liver, adrenal glands and spleen metastases. A needle biopsy of a liver lesion revealed metastatic melanoma of similar characteristics to the original tumor. We suggest that progesterone treatment triggered proliferation of so far dormant micrometastases that were controlled during CSF470 vaccine treatment.

Conclusion

The use of progesterone in patients with melanoma that are under immunological treatments should be carefully considered, since progesterone could modify the balance of pro-inflammatory and Th1 functions to a regulatory and anti-inflammatory profile of the immune system that could have an impact in tumor progression.

Keywords:
Melanoma; Vaccine treatment; Progesterone treatment; Metastasis